



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/284,787	08/16/1999	THOMAS EMRICH	BMID9913US	2784
23690	7590	06/20/2005	EXAMINER	
Roche Diagnostics Corporation 9115 Hague Road PO Box 50457 Indianapolis, IN 46250-0457			ZEMAN, ROBERT A	
			ART UNIT	PAPER NUMBER
			1645	

DATE MAILED: 06/20/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No.

09/284,787

Applicant(s)

EMRICH ET AL.

Examiner

Robert A. Zeman

Art Unit

1645

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 11 April 2005.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 18-25 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 18-25 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

## **DETAILED ACTION**

### ***Continued Examination Under 37 CFR 1.114***

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 1-11-2005 has been entered.

The amendment filed on 4-11-2005 is acknowledged. Claims 18-21 and 23 have been amended. Claims 18-25 are pending and currently under examination.

### ***Claim Rejections Withdrawn***

The rejection of claims 20-25 under 35 U.S.C. 112, first paragraph, for failing to satisfy the biological deposit requirements with regard to the mouse myeloma cell line P3x63-Ag8.653 is withdrawn in light of the amendment thereto.

### ***Claim Rejections Maintained and New Grounds of Rejection***

#### ***35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless —

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Art Unit: 1645

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 18-19 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Hinds et al. (Journal of Medicinal Chemistry, 1991 Vol. 34, No. 6, pages 1777-1789 - IDS-6).

The instant claims are drawn to monoclonal antibodies with a binding affinity of  $10^8$  to  $10^{10}$  M<sup>-1</sup> for the sequence YPYDVPDYA (SEQ ID NO:1) wherein said antibodies are drawn against a 13- or 14-amino acid containing epitope of human influenza virus haemagglutinin.

**Applicant argues:**

1. Hinds et al. use a 19 amino acid-containing haemagglutinin peptide as the immunogen for raising monoclonal antibodies whereas the instant claims use a 13- or 14- amino acid peptide.
2. The disclosure by Hinds et al. does not render the instant invention obvious.

Art Unit: 1645

Applicant's arguments have been fully considered and deemed non-persuasive.

The instant claims are drawn to monoclonal antibodies with a binding affinity of  $10^8 M^{-1}$  for the amino acid sequence of YPYDVDPDYA. Hinds et al. disclose antibodies with a binding specificity to the sequence YPYDVDPDYA (see abstract). Although Hinds et al. disclose the same product they do not disclose the claimed method of making. However, it should be noted that the instant claims constitute Product-by-Process type claims. In Product-by-Process type claims, the process of producing the product is given no patentable weight since it does not impart novelty to a product when the product is taught by the prior art. See *In re Thorpe*, 227 USPQ 964 (CAFC 1985); *In re Marosi*, 218 USPQ 289, 292-293 (CAFC 1983) and *In re Brown*, 173 USPQ 685 (CCPA 1972). Consequently, even if a particular process used to prepare a product is novel and unobvious over the prior art, the product *per se*, even when limited to the particular process, is unpatentable over the same product taught in by the prior art. See *In re King*, 107 F.2d 618, 620, 43 USPQ 400, 402 (CCPA 1939); *In re Merz*, 97 F.2d 599, 601, 38 USPQ 143-145 (CCPA 1938); *In re Bergy*, 563 F.2d 1031, 1035, 195 USPQ 344, 348 (CCPA 1977) *vacated* 438 US 902 (1978); and *United States v. Ciba-Geigy Corp.*, 508 F. Supp. 1157, 1171, 211 USPQ 529, 543 (DNJ 1979). Finally, since the Patent Office does not have the facilities for examining and comparing Applicant's composition with the compositions of the prior art reference, the burden is upon Applicant to show a distinction between the material, structural and functional characteristics of the claimed composition and the composition of the prior art. See *In re Best*, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977).

With regard to Applicant's assertion that Hinds et al does not render instant invention obvious, said methods are standard practice in the art. Moreover, for antibodies specific for a given

Art Unit: 1645

antigen, the  $K_d$  usually varies from about  $10^{-7}$  M to  $10^{-11}$  M (see Cellular and Molecular Immunology, page 54). Therefore since Hinds et al. disclose antibodies with a binding specificity to the sequence YPYDVPDYA (see abstract), some of said antibodies would have the requisite affinities. Additionally, it would be obvious to one of skill in the art to select those antibodies with the highest affinities.

***35 USC § 103***

Claims 18-21 and 23-25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hinds et al. (Journal of Medicinal Chemistry, 1991 Vol. 34, No. 6, pages 1777-1789 - IDS-6) in view of Kuby (Immunology, Second Edition, W.H. Freeman and Company, 1994, pages 160-164).

The instant invention is drawn to monoclonal antibodies with a binding affinity of  $10^8$  to  $10^{10}$   $M^{-1}$  for the sequence YPYDVPDYA (SEQ ID NO:1) wherein said antibodies are drawn against a 13- or 14-amino acid containing epitope of human influenza virus haemagglutinin and methods of making said monoclonal antibodies utilizing peptides comprising the sequence YPYDVPDYA (and derivatives thereof), rodents and a murine myeloma cell line.

**Applicant argues:**

1. Hinds et al. use a 19 amino acid-containing haemagglutinin peptide as the immunogen for raising monoclonal antibodies whereas the instant claims use a 13- or 14- amino acid peptide.
2. The disclosures by Hinds et al. either alone or in combination with Kuby do not render the instant invention obvious.

Applicant's arguments have been fully considered and deemed non-persuasive.

Instant claims 18-21 are drawn to monoclonal antibodies with a binding affinity of  $10^8 M^{-1}$

Art Unit: 1645

for the amino acid sequence of YPYDVDPDYA. Hinds et al. disclose antibodies with a binding specificity to the sequence YPYDVDPDYA (see abstract). Although Hinds et al. disclose the same product they do not disclose the claimed method of making. However, it should be noted that the instant claims constitute Product-by-Process type claims. In Product-by-Process type claims, the process of producing the product is given no patentable weight since it does not impart novelty to a product when the product is taught by the prior art. See *In re Thorpe*, 227 USPQ 964 (CAFC 1985); *In re Marosi*, 218 USPQ 289, 292-293 (CAFC 1983) and *In re Brown*, 173 USPQ 685 (CCPA 1972). Consequently, even if a particular process used to prepare a product is novel and unobvious over the prior art, the product *per se*, even when limited to the particular process, is unpatentable over the same product taught in by the prior art. See *In re King*, 107 F.2d 618, 620, 43 USPQ 400, 402 (CCPA 1939); *In re Merz*, 97 F.2d 599, 601, 38 USPQ 143-145 (CCPA 1938); *In re Bergy*, 563 F.2d 1031, 1035, 195 USPQ 344, 348 (CCPA 1977) *vacated* 438 US 902 (1978); and *United States v. Ciba-Geigy Corp.*, 508 F. Supp. 1157, 1171, 211 USPQ 529, 543 (DNJ 1979). Finally, since the Patent Office does not have the facilities for examining and comparing Applicant's composition with the compositions of the prior art reference, the burden is upon Applicant to show a distinction between the material, structural and functional characteristics of the claimed composition and the composition of the prior art. See *In re Best*, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977).

With regard to Applicant's assertion that Hinds et al does not render instant invention obvious, said methods are standard practice in the art. Moreover, for antibodies specific for a given antigen, the  $K_d$  usually varies from about  $10^{-7}$  M to  $10^{-11}$  M (see Cellular and Molecular Immunology, page 54). Therefore since Hinds et al. disclose antibodies with a binding specificity to the sequence

Art Unit: 1645

YPYDVPDYA (see abstract), some of said antibodies would have the requisite affinities.

Additionally, it would be obvious to one of skill in the art to select those antibodies with the highest affinities.

As outlined previously, Hinds et al. disclose antibodies with a binding specificity to the sequence YPYDVPDYA (see abstract). Hinds et al. do not disclose the exact method steps recited in the instant claims. Specifically, Hinds et al. does not explicitly disclose the use of Lou/C rats. However, as disclosed by Kuby, the methodology for producing monoclonal antibodies is well known in the art. An animal (rodent) is challenged with the antigen of interest. Spleen cells (source of primed B cells) are harvested from said animal and fused with HGPRT; IgG immortalized myeloma cells in polyethylene glycol. The resulting hybridomas are selected using HAT containing medium and screened for antibody production. Hybridomas producing the desired antibody are then subcloned. Since the production a given monoclonal antibody is predicated on the antigen used to immunize the animal, the selection of a specific animal and/or myeloma cell line merely constitutes a conventional alternative to the method disclosed by Kuby and hence would have been obvious to one of skill in the art.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 22 is rejected under 35 U.S.C. 112, second paragraph, as it is dependent on rejected claims. Claim 22 would be allowable if presented in an independent form.



Art Unit: 1645

***Conclusion***

No claim is allowed.

Claim 22 would be allowable if presented in an independent form.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert A. Zeman whose telephone number is (571) 272-0866. The examiner can normally be reached on Monday- Thursday, 7am -5:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith can be reached on (571) 272-0864. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Robert A. Zeman

June 14, 2005